APLLTD Q2 FY27 Results & Earnings Analysis
Sentiment: Great (Confidence: high)
Earnings Summary
Alembic Pharmaceuticals delivered strong Q2 FY27 with 36% YoY revenue growth to INR2,603 crores, 78% EBITDA growth, and 81% PAT growth, driven by U.S. generics (72% YoY), API (39% YoY), and India recovery (11% YoY). EBITDA margin expanded 520 bps YoY to 22.2%. Management raised FY27 revenue growth guidance to 20-25% from mid-teens, expects H2 margins to hold ~22%, and targets ~20% EBITDA margin in FY28/29 with U.S. branded breakeven by H1 FY28. DifGen collaboration adds 20+ complex generics for future growth. Balance sheet healthy with net debt <1x EBITDA.
Management Tone
- Prepared Remarks: Great — Prepared remarks highlighted exceptional growth across businesses, margin expansion, and a raised guidance, with clear drivers and positive outlook.
- Q&A Session: Good — Analysts asked detailed questions on U.S. business sustainability, margins, and India recovery; management provided direct and confident responses with some quantification, though certain product-level details were withheld.
Revenue Growth Drivers
- Volume growth in U.S. generics base portfolio (23% ex-bosutinib)
- New launches including bosutinib exclusivity
- API volume-led growth (39% YoY) including CMO deliveries
Growth vs Margin Focus
Management raised revenue guidance and emphasized margin expansion through operating leverage and U.S. branded breakeven, while continuing R&D and pipeline investments.
About Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited (APLLTD) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.